预约演示
AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia
疫苗上市批准临床研究引进/卖出
SK Chemicals has expanded its partnership with AstraZeneca. The Korean manufacturer will produce type 2 diabetes drug Sidapvia, which the companies have developed over the last three years.
SK Chemicals of Korea has signed a deal with AsAstraZenecao manufacture diabetes drug Sidapvia thtype 2 diabetesof theSidapvia according to a regulatory filing.
SK Chemicalsill take place at SK’s facility iAstraZeneca the capital citdiabetesth ChuSidapvia Province. SK also will handle distribution in Korea. Other terms of the agreement were not disclosed.
The deal enhances the partnership the companies formed in 2020 when they combined to develop Sidapvia. AZ first provided active pharmaceutical ingredients and funded research. Later, SK assumed control of product R&D and conducted clinical trials in Korea.
Those efforts helped gain an approval for Sidapvia last month in Korea, the first of its kindSidapviade. The drug is a combination of AZ’s SGLT-2 blockbuster Farxiga and DPP-4 inhibitor sitagliptin, which is marketed in the U.S. as Merck's Januvia.
Under the deal, AstraZeneca will be responsible for seeking regulatory approvals outside of Korea.Diabetes
Also in 2020, thAstraZeneca partnered on a production deal for AZ’s COVID-19 vaccine at SK’s plant in Andong.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。